Press coverage about Quest Diagnostics (NYSE:DGX) has trended positive on Saturday, according to Alpha One Sentiment Analysis. Alpha One, a subsidiary of Accern, ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quest Diagnostics earned a daily sentiment score of 0.26 on Alpha One’s scale. Alpha One also gave media coverage about the medical research company an impact score of 88 out of 100, indicating that recent press coverage is very likely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have effected Alpha One Sentiment Analysis’s rankings:
- Quest Diagnostics Incorporated (NYSE:DGX) Files An 8-K Submission of Matters to a Vote of Security Holders (4-traders.com)
- Investor Arena: Keeping an Eye on Quest Diagnostics Inc (DGX) – SKV News (skvnews.com)
- Ronna Sue Cohen Buys United Parcel Service Inc, Quest Diagnostics Inc, SPDR MidCap Trust Series … (nasdaq.com)
- The ProShare Advisors LLC Has $1.807 Million Stake in Quest Diagnostics Inc (DGX) – BangaloreWeekly (bangaloreweekly.com)
- [$$] More American Workers Are Testing Positive for Drugs (finance.yahoo.com)
Quest Diagnostics (NYSE:DGX) opened at 105.89 on Friday. The stock has a market cap of $14.49 billion, a PE ratio of 21.31 and a beta of 0.68. The company’s 50-day moving average is $103.07 and its 200 day moving average is $94.96. Quest Diagnostics has a 52 week low of $75.20 and a 52 week high of $108.21.
Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, April 20th. The medical research company reported $1.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.18 by $0.15. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.87 billion. Quest Diagnostics had a return on equity of 14.61% and a net margin of 8.56%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 EPS. On average, analysts expect that Quest Diagnostics will post $5.56 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, July 24th. Stockholders of record on Monday, July 10th will be paid a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a dividend yield of 1.70%. The ex-dividend date of this dividend is Thursday, July 6th. Quest Diagnostics’s payout ratio is 40.00%.
A number of research firms recently weighed in on DGX. Argus began coverage on shares of Quest Diagnostics in a research report on Friday, May 12th. They set a “hold” rating and a $102.00 price target on the stock. Evercore ISI reissued an “in-line” rating and set a $104.50 price target (up from $102.00) on shares of Quest Diagnostics in a research report on Monday, April 24th. Raymond James Financial, Inc. raised shares of Quest Diagnostics from a “market perform” rating to an “outperform” rating and set a $116.00 price target on the stock in a research report on Friday, April 21st. Barclays PLC raised their price target on shares of Quest Diagnostics from $92.00 to $98.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 7th. Finally, Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $102.00 price target on the stock in a research report on Tuesday, January 24th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $106.58.
TRADEMARK VIOLATION NOTICE: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/05/20/quest-diagnostics-dgx-receiving-favorable-media-coverage-analysis-finds-updated-updated-updated.html.
In related news, Director Jenne K. Britell sold 6,111 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $104.03, for a total transaction of $635,727.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael E. Prevoznik sold 440 shares of the business’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $97.39, for a total value of $42,851.60. Following the sale, the senior vice president now owns 41,734 shares of the company’s stock, valued at $4,064,474.26. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 57,213 shares of company stock valued at $5,732,460. Corporate insiders own 1.50% of the company’s stock.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.